{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:19:16Z","timestamp":1763018356838,"version":"3.45.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.05.027","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T11:12:30Z","timestamp":1622977950000},"page":"807-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Sarah A.","family":"Holstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccolo","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Brownstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Demolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Foureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Gormley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2021.05.027_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2017.12.774","article-title":"BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: summary and recommendations from the organizing committee","volume":"24","author":"Holstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.027_bib0002","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.bbmt.2018.11.001","article-title":"Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"25","author":"Holstein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0003","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","article-title":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.027_bib0004","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.bbmt.2020.06.011","article-title":"Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.027_bib0005","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2021.05.027_bib0008","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2021.05.027_bib0009","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0010","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.jtct.2021.05.027_bib0011","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jtct.2021.05.027_bib0012","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.027_bib0013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","article-title":"Peripheral immunotype correlates with minimal residual disease status and is modulated by immunomodulatory drugs in multiple myeloma","volume":"25","author":"Bhutani","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","article-title":"T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma","volume":"26","author":"Lucas","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0015","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3390\/cancers12113245","article-title":"Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma","volume":"12","author":"Papadimitriou","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2021.05.027_bib0016","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.027_bib0017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.027_bib0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jtct.2020.11.009","article-title":"Serological response to vaccination after autologous transplantation for multiple myeloma is associated with improved progression-free and overall survival","volume":"27","author":"Merz","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2021.05.027_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2013.218","article-title":"Biomarker enrichment strategies: matching trial design to biomarker credentials","volume":"11","author":"Freidlin","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.027_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40425-016-0179-0","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations","volume":"4","author":"Dobbin","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-136907","article-title":"Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial","volume":"136","author":"Gay","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-137351","article-title":"Impact of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) on outcome: results of newly diagnosed transplant-eligible multiple myeloma (MM) patients enrolled in the Forte Trial","volume":"136","author":"Oliva","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-137075","article-title":"Poor prognosis of multiple myeloma predicted by high levels of circulating plasma cells is independent from other high-risk features but is modulated by the achievement of minimal residual disease negativity","volume":"136","author":"Bertamini","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","volume":"132","author":"Gay","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-136403","article-title":"Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: progressive versus stable myeloma precursor disease","volume":"136","author":"Oben","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0026","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jtct.2021.05.027_bib0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.jtct.2021.05.027_bib0028","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.027_bib0029","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1097\/HS9.0000000000000502","article-title":"A journey through myeloma evolution: from the normal plasma cell to disease complexity","volume":"4","author":"Da Via","year":"2020","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.jtct.2021.05.027_bib0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtct.2021.05.027_bib0031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2013.00012","article-title":"Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow","volume":"4","author":"Bernardini","year":"2013","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.jtct.2021.05.027_bib0032","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.027_bib0033","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jtct.2021.05.027_bib0034","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-142622","article-title":"Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma","volume":"136","author":"Merz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0036","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.027_bib0037","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","article-title":"Induction of intestinal Th17 cells by segmented filamentous bacteria","volume":"139","author":"Ivanov","year":"2009","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.jtct.2021.05.027_bib0038","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/bloodadvances.2019032276","article-title":"Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition","volume":"3","author":"Pianko","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.027_bib0039","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.24352","article-title":"Reduction in C-reactive protein indicates successful targeting of the IL-1\/IL-6 axis resulting in improved survival in early stage multiple myeloma","volume":"91","author":"Lust","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.027_bib0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0041","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood-2019-123974","article-title":"Single-cell characterization of the multiple myeloma (MM) immune microenvironment identifies CD27-negative T cells as potential source of tumor-reactive lymphocytes","volume":"134","author":"Botta","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0042","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2019-127717","article-title":"Qip-mass spectrometry in high risk smoldering multiple myeloma patients included in the GEM-CESAR Trial: comparison with conventional and minimal residual disease IMWG response assessment","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2021.05.027_bib0043","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0044","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2021.05.027_bib0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s12276-020-0422-0","article-title":"Single-cell transcriptomics in cancer: computational challenges and opportunities","volume":"52","author":"Fan","year":"2020","journal-title":"Exp Mol Med"},{"issue":"8","key":"10.1016\/j.jtct.2021.05.027_bib0046","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41587-019-0206-z","article-title":"Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion","volume":"37","author":"Satpathy","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.jtct.2021.05.027_bib0047","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","article-title":"Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans","volume":"21","author":"Galletti","year":"2020","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2021.05.027_bib0048","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2018.09.009","article-title":"High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice","volume":"49","author":"Crinier","year":"2018","journal-title":"Immunity"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0049","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2018-99-117531","article-title":"Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and Tigit on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients","volume":"132","author":"Neri","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.027_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0051","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2021.05.027_bib0052","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2018.10.005","article-title":"Translating the anti-myeloma activity of Natural Killer cells into clinical application","volume":"70","author":"Fionda","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2021.05.027_bib0053","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2018.36.15_suppl.8006","article-title":"Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2021.05.027_bib0054","doi-asserted-by":"crossref","first-page":"617","DOI":"10.18609\/cgti.2019.070","article-title":"Genetically modified natural killer cells: an \"off-the-shelf\" immunotherapy for cancer","volume":"5","author":"Sarkar","year":"2019","journal-title":"Cell Gene Therapy Insights"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol Ther"},{"issue":"21","key":"10.1016\/j.jtct.2021.05.027_bib0056","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2021.05.027_bib0057","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.027_bib0058","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-02901-y","article-title":"Natural killer cells efficiently target multiple myeloma clonogenic tumor cells [e-pub ahead of print March 12, 2021]","author":"Leivas","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"10.1016\/j.jtct.2021.05.027_bib0059","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0060","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0061","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019","volume":"7","author":"Lemal","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jtct.2021.05.027_bib0062","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.jtct.2021.05.027_bib0063","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.05.027_bib0064","unstructured":"Li C, Wang J, Wang D. A phase 1 study of CT103A, a fully human BCMA targeting CAR T CELL, in subjects with relapsed\/refractory multiple myeloma. Available at: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293963\/chunrui.li.a.phase.1.study.of.ct103a.a.fully.human.bcma.targeting.car.t.cell.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dcar+t+cell 2021."},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.bbmt.2020.07.023","article-title":"Baseline gut microbiota composition is associated with major infections early after hematopoietic cell transplantation","volume":"26","author":"Murthy","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0066","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.bbmt.2020.07.011","article-title":"Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Tanaka","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.05.027_bib0067","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.bbmt.2020.08.009","article-title":"Impact of intestinal microbiota on reconstitution of circulating monocyte, dendritic cell, and natural killer cell subsets in adults undergoing single-unit cord blood transplantation","volume":"26","author":"Konuma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.027_bib0068","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-019-0155-8","article-title":"Gut microbiome and CAR-T therapy","volume":"8","author":"Abid","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.05.027_bib0069","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2018-99-118628","article-title":"Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity","volume":"132","author":"Smith","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2021.05.027_bib0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2021.05.027_bib0071","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2020.09.030","article-title":"NK cell adoptive immunotherapy of cancer: evaluating recognition strategies and overcoming limitations","volume":"27","author":"Sanchez","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:33Z","timestamp":1763003073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721009465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721009465"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.027","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}